Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 26, Issue 4, 2014, Pages 411-415

  Kurtz, Steven P ^a   Buttram, Mance E ^a   Surratt, Hilary L ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

ARV; Diversion; MSM; PrEP

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; DISEASE TRANSMISSION; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; PATIENT COMPLIANCE; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; STRUCTURED INTERVIEW; SUBSTANCE ABUSE; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; COMMERCE; FLORIDA; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; QUESTIONNAIRES; RISK-TAKING; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; UNSAFE SEX; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84892576353     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2013.837139     Document Type: Article

References (26)

1. Associated Press. (1995, December 25). AIDS drugs surface on black market. New York Times, p. 43.
2. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., & Moss, A. (2001). Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181-1183. doi:10.10 97/00002030-200106150-00015
3. Centers for Disease Control and Prevention. (2012). Interim guidance for clinicians considering the use of pre-exposure prophylaxis for the prevention of HIV infection in heterosexually active adults. Morbidity and Mortality Weekly Report, 61, 586-589. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm6131a2.htm
4. Curran, J. W., & Crosby, R. A. (2013). Pre-exposure prophylaxis for HIV: Who will benefit and what are the challenges? American Journal of Preventive Medicine, 44 (1S2), S163-S166. doi:10.1016/j.amepre.2012.10.005
5. Dennis, M. L., Titus, J. C., White, M. K., Unsicker, J. I., & Hodgkins, D. (2002). Global appraisal of individual needs-Initial (GAIN-I). Bloomington, IL: Chestnut Health Systems.
6. Dorschner, J. (2005, June 30). Activists: HIV care scam uses homeless. Miami Herald, p. 1A.
7. Flaherty, M. P., & Gaul, G. M. (2003, December 19). Florida Medicaid fraud costs millions, report says. Washington Post, p. E03.
8. Food and Drug Administration. (2012). Truvada for PrEP fact sheet: Ensuring safe and proper use. Retrieved from http://www.fda.gov/downloads/ newsevents/newsroom/fact sheets/ucm312279.pdf
9. Glasgow, K. (1999, October 21). The new dealers: They're poor, black, and HIV-positive. Their product? The AIDS medications intended to cure them. Miami New Times. Retrieved from http://www.miaminewtimes.com/1999-10-21/news/the-new- dealers/
10. Grelotti, D. J., Closson, E. F., & Mimiaga, M. J. (2013). Pretreatment antiretroviral exposure from recreational use. The Lancet Infectious Diseases, 13(1), 10-12. doi:10.10 16/S1473-3099(12)70294-3
11. Hurt, C. B., Eron, J. J., & Cohen, M. S. (2011). Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clinical Infectious Diseases, 53(12), 1265-1270. doi:10.1093/cid/cir684
12. Inciardi, J. A., Surratt, H. L., Kurtz, S. P., & Burke, J. J. (2006). The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Substance Use and Misuse, 41(2), 255-264. doi:10.1080/10826080500391829
13. Inciardi, J. A., Surratt, H. L., Kurtz, S. P., & Cicero, T. J. (2007). Mechanisms of prescription drug diversion among drug-involved club and street-based populations. Pain Medicine, 8(2), 171-183. doi:10.1111/j.1526-4637. 2006. 00255.x
14. Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E. (2012). The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Annals of Internal Medicine, 156(8), 541-550. doi:10.7326/0003-4819-156-8-201204170-00004
15. Kippax, S. (2012). Effective HIV prevention: The indispensable role of social science. Journal of the International AIDS Society, 15(2), 17357. doi:10.7448/IAS.15.2.17357
16. Koenig, L. J., Lyles, C., & Smith, D. K. (2013). Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: Lessons learned from trials and treatment studies. American Journal of Preventive Medicine, 44(IS2), S91-S98. doi:10.1016/j.amepre.2012.09.047
17. Krakower, D. S., Mimiaga, M. J., Rosenberger, J. G., Novak, D. S., Mitty, J. A., White, J. M., & Mayer, K. H. (2012). Limited awareness and low immediate uptake of preexposure prophylaxis among men who have sex with men using an internet social networking site. PLoS ONE, 7(3), e33119. doi:10.1371/journal.pone.0033119.t005
18. Liu, A. Y., Kittredge, P. V., Vittinghoff, E., Raymond, H. F., Ahrens, K., Matheson, T., ... Buchbinder, S. P. (2008). Limited knowledge and use of HIV post-and pre-exposure prophylaxis among gay and bisexual men. Journal of Acquired Immune Deficiency Syndrome, 47(2), 241-247. doi:10.1097/QAI. 0b013e31815e4041
19. Mansergh, G., Koblin, B. A., Colfax, G. N., McKirnan, D. J., Flores, S. A., & Hudson, S. M. (2010). Preefficacy use and sharing of antiretroviral medications to prevent sexuallytransmitted HIV infection among us men who have sex with men. Journal of Acquired Immune Deficiency Syndrome, 55(2), e14-e16. doi:10.1097/QAI.0b013e3181f 27616
20. Mimiaga, M. J., Case, P., Johnson, C. V., Safren, S. A., & Mayer, K. H. (2009). Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. Journal of Acquired Immune Deficiency Syndrome, 50(1), 77-83. doi:10.1097/QAI.0b013e31818d5a27
21. O'Grady, C., Surratt, H. L., Kurtz, S. P. (2013, June 15). Antiretroviral medication diversion in South Florida: Prescription types and motivations. Poster session presented at the 75th Annual Meeting of the College on Problems of Drug Dependence, San Diego, California.
22. Philpott, S. (2013). Social justice, public health ethics, and the use of HIV pre-exposure prophylaxis. American Journal of Preventive Medicine, 44(IS2), S137-S140. doi:10.1016/j.amepre.2012.09.029
23. Smith, D., Grant, R., Weidle, P., Lansky, A., Mermin, J., & Fenton, K. (2011). Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbidity and Mortality Weekly Report, 60 (3), 65-68. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1. htm
24. Surratt, H. L., & Kurtz, S. P. (2013). A national perspective on the abuse and diversion of prescription drugs. Paper presented at the Nova Southeastern University Faculty Symposium, Nova Southeastern University. Retrieved from http://arsh.nova.edu/presentations/forms/a-national-perspective- on-the-abuse-and-diversion-of-prescription-drugs.pdf
25. Surratt, H. L., Kurtz, S. P., Cicero, T. J., O'Grady, C., & Levi-Minzi, M. A. (2013). Antiretroviral medication diversion among HIV-positive substance abusers in South Florida. American Journal of Public Health, 103(6), 1026-1028. doi:10.2105/AJPH.2012.301092
26. Weber, J., Tatoud, R., & Fidler, S. (2010). Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: The strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS, 24(Suppl. 4), S27-S39. doi:10.1097/01.aids.0000390705.73759.2c